Novo Nordisk Levemir To Launch Within Next 12 Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-acting insulin analogue clears FDA June 17 for treatment of type 1 and type 2 diabetes. Firm says approval makes it the only company in U.S. with a "full range" of short-acting and long-acting insulin analogues.